Adequate hematological, hepatic and renal functions
Eastern Cooperative Oncology Group (ECOG) Performance status 0-1.
Estimated life expectancy of \> 6 months.
Negative pregnancy test for female patients with child-bearing potential.
No history of retinal disorder.
No history of glucose-6-phosphate dehydrogenase deficiency (G6PD) .
Considered to be DTP-signature high to receive HCQ treatment
You may not be if
Women who are pregnant or nursing.
Have received radiotherapy, chemotherapy, biological therapy, or investigational treatment less than four weeks (six weeks for nitrosoureas or mitomycin C) prior to first dose of FOLFIRI-beva or have not recovered from all acute toxicities from prior treatments to grade 1 or less, with the exception of alopecia and those deemed not to affect safety assessment.
Have concurrent malignancy with exception of malignancy that was treated curatively and without evidence of recurrence within 3 years of study enrollment, or fully resected basal or squamous cell skin cancer and any carcinoma in situ which are considered to be of low risk of recurrence.
Have had major surgery within 28 days of study enrollment. Placement of a venous access device within 28 days of starting therapy is allowed.
Have any medical condition that would impair the administration of oral agents including significant bowel resection, inflammatory bowel disease or uncontrolled nausea or vomiting.
Clareo Health | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
